Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Guardado en:
Detalles Bibliográficos
Autores principales: Shahneen Sandhu, Grant A McArthur, Kate Drummond, Alison Weppler, Tony Papenfuss, Amir Iravani, Belinda Lee, Richard J Young, Kortnye Smith, Peter Kar Han Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Christopher Angel, Hanxian Aw Yeang, Ismael A Vergara, David Kok, Paul Joseph Neeson, Karen E Sheppard, Benjamin J Solomon
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/b420b6d4298340e19b198383efd6e211
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares